Opioid use in chronic pain

Acta Anaesthesiologica Scandinavica

Volumn 41, Issue 1 II, 1997, Pages 175-183

  McQuay, H J ^a  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

adverse effects; cancer pain; chronic pain; opioids

Indexed keywords

BUTORPHANOL; MORPHINE; NALBUPHINE; OPIATE; PENTAZOCINE; PETHIDINE;

CANCER PAIN; CHRONIC PAIN; CONFERENCE PAPER; CONSTIPATION; DRUG EFFICACY; DRUG TOLERANCE; DRUG USE; DYSPHORIA; HUMAN; KIDNEY FAILURE; LIVER FAILURE; NAUSEA; NEUROPATHY; PRESCRIPTION; PRIORITY JOURNAL; VOMITING;

EID: 0031028092     PISSN: 00015172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-6576.1997.tb04634.x     Document Type: Conference Paper

References (71)

1. McQuay HJ. Opioids in chronic pain. Br J Anaesth 1989: 63: 213-226.
2. Nagle C, McQuay HJ. Opiate receptors; their role in effect and side-effect. Curr Anaesth Crit Care 1990: 1: 247-252.
3. McQuay HJ. Opioid clinical pharmacology and routes of administration. Br Med Bull 1991: 47: 703-717.
4. McQuay HJ. The logic of alternative routes [editorial]. J Pain & Symptom Manage 1990: 5: 75-77.
5. Jadad AR, Browman GP. The WHO Analgesic Ladder for Cancer pain management. JAMA 1995: 274: 1870-1873.
6. Hanks G, et al. WHO guidelines. Br Med J, in press.
7. Levine MN, Sackett DL, Bush H. Heroin vs. morphine for cancer pain? Arch Intern Med 1986: 146: 353-356.
8. Portenoy RK, Foley KM, Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain 1990: 43: 273-286.
9. Arner S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1988: 33: 11-23.
10. Kupers RC, Konings H, Adriaensen H, Gybels JM. Morphine differentially affects the sensory and affective pain ratings in neurogenic and idiopathic forms of pain. Pain 1991: 47: 5-12.
11. Tasker RR, Tsuda T, Hawrylyshyn P. Clinical neurophysiological investigation of deafferentation pain. In: Bonica JJ, Lindblom U, Iggo A, eds. Advances in Pain Research & Therapy. Vol. 5. Proc 3rd World Congress on Pain. New York: Raven Press, 1983: 713-738.
12. Rowbotham MC, Reisner-Keller LA, Fields HL. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 1991: 41: 1024-1028.
13. Jadad AR, Carroll D, Glynn CJ, Moore RA, McQuay HJ. Morphine responsiveness of chronic pain: double-blind randomised crossover study with patient-controlled analgesia. Lancet 1992: 339: 1367-1371.
14. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990: 41: 273-281.
15. Banning A, Sjøgren P, Henriksen H. Treatment outcome in a multidisciplinary cancer pain clinic. Pain 1991: 47: 129-134.
16. Bruera E, Fainsinger R, MacEachern T, Hanson J. The use of methylphenidate in patients with incident cancer pain receiving regular opiates. A preliminary report. Pain 1992: 50: 75-77.
17. Schulze S, Sommer P, Bigler D, Honnens M, Shenkin A, Cruickshank AM et al. Effect of combined prednisolone, epidural analgesia, and indomethacin on the systemic response after colonic surgery. Arch Surg 1992: 127: 325-31.
18. Brose WG, Cousins MJ. Subcutaneous lidocaine for treatment of neuropathic cancer pain. Pain 1991: 45: 145-148.
19. McQuay H. Epidural Analgesics. In: Wall P, Melzack R, eds. Textbook of Pain. 3rd edit. London: Churchill Livingstone, 1994: 1025-1034.
20. Max MB, Lynch SA, Muir J, Shoaf SF, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992: 326: 1250-1256.
21. Sindrup SH, Gram LF, Brøsen K, Eshøj O, Mogensen EF. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990: 42: 135-144.
22. McQuay HJ, Carroll D, Glynn CJ. Low dose amitriptyline in the treatment of chronic pain. Anaesthesia 1992: 47: 646-52.
23. McQuay HJ, Carroll D, Glynn CJ. Dose-response for analgesic effect of amitriptyline in chronic pain. Anaesthesia 1993: 48: 281-285.
24. McQuay H, Carroll D, Jadad AR, Wiffen P, Moore A. Anticonvulsant drugs for management of pain - a systematic review. Br Med J 1995: 311: 1047-1052.
25. McQuay H, Nye BA, Carroll D, Wiffen PJ, Tramér M, Moore RA. A systematic review of antidepressants in neuropathic pain. Pain, submitted.
26. Kalso E. Painful diabetic neuropathy. Curr Opin Anaesthesiol 1993: 6: 857-860.
27. Byas-Smith MG, Max MB, Gracely RH, Bennett GJ. Intravenous ketamine and alfentanil in patients with chronic causalgic pain and allodynia. Abstracts - 7th World Congress on Pain 1993: 454-455.
28. Backonja M, Arndt G, Gombar KA, Check B, Zimmermann M. Response of chronic neuropathic pain syndromes to ketamine: a preliminary study. Pain 1994: 56: 51-57.
29. Stannard CF, Porter GE. Ketamine hydrochloride in the treatment of phantom limb pain. Pain 1993: 54: 227-230.
30. Bruera E, Velasco-Leiva A, Spachynski K, Fainsinger R, Miller MJ, MacEachern T. Use of the Edmonton Injector for parenteral opioid management of cancer pain: a study of 100 consecutive patients. J Pain & Symptom Manage 1993: 8: 525-528.
31. Rosow C. Remifentanil: a unique opioid analgesic. Anesthesiology 1993: 79: 875-876.
32. Jadad AR, McQuay HJ. Pain measurement. In: Fairbank J, Pysent P, Carr A, eds. Outcome Measures in Trauma. Oxford: Butterworth Heinemann, 1994: 17-24.
33. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, in press.
34. Colpaert F, Niemegeers C, Janssen P, Maroli A. The effects of prior fentanyl administration and of pain on fentanyl analgesia: tolerance to and enhancement of narcotic analgesia. J Pharmacol Exp Ther 1980: 213: 418-426.
35. Houde R. The analgesic connection: the Nathan B. Eddy memorial lecture. In: Harris L, ed. Problems of drug dependence. 55. NIDA Res Monogr, 1985: 4-13.
36. Houde R, Wallenstein S, Beaver W. Evaluation of analgesics in patients with cancer pain. In: Lasagna L, ed. International Encyclopedia of Pharmacology and Therapeutics. Oxford: Pergamon Press, 1966: 59-98.
37. Walsh T, Baxter R, Bowerman K, Leber B. High-dose morphine and respiratory function in chronic cancer pain. Pain 1981: S1: 39.
38. Regnard C, Badger C. Opioids, sleep and the time of death. Palliat Med 1987: 1: 107-110.
39. Hanks GW, Twycross RG, Lloyd JW. Unexpected complication of successful nerve block. Anaesthesia 1981: 36: 37-39.
40. McQuay HJ. Potential problems of using both opioids and local anaesthetic [letter]. Br J Anaesth 1988: 61: 121.
41. Arita H, Kogo N, Ichikawa K. Locations of medullary neurons with nonphasic discharges excited by stimulation of central and/or peripheral chemoreceptors and by activation of nociceptors in cat. Brain Res 1988: 442: 1-10.
42. Porter J, Jick H. Addiction rate in patients treated with narcotics. N Engl J Med 1980: 302: 123.
43. Morrison J, Hill G, Dundee J. Studies of drugs given before anaesthesia XV: evaluation of the method of study after 10,000 observations. Br J Anaesth 1968: 40: 890-900.
44. Wallenstein S, Rogers A, Kaiko R, Houde R. Nalbuphine clinical analgesic studies. In: Foley K, Inturrisi C, eds. Opioid analgesics in the management of cancer pain, Advances in Pain Research and Therapy, Vol. 8. New York: Raven Press, 1986: 247-252.
45. Kalso E, Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 1990: 47: 639-646.
46. Houde R. Discussion. In: Foley K, Inturrisi C, eds. Opioid analgesics in the management of cancer pain, Advances in Pain Research and Therapy, Vol. 8. New York: Raven Press, 1986: 261-263.
47. Szeto H, Inturrisi C, Houde R, Saal S, Cheigh J, Reidenberg M. Accumulation of norperidine, an active metabolite of meperidine, in patients with renal failure or cancer. Ann Intern Med 1977: 86: 738-741.
48. Boreus L, Odar-Cederlof I, Bondesson U, Holmberg L, Heyner L. Elimination of meperidine and its metabolites in old patients compared to young patients. In: Foley K, Inturrisi C, eds. Opioid analgesics in the Management of Cancer Pain, Advances in Pain Research & Therapy, Vol. 8. New York: Raven Press, 1986: 167-169.
49. Inturrisi C, Max M, Umans J, Schultz M, Shin S, Foley K et al. The pharmacokinetics of heroin in patients with chronic pain. N Engl J Med 1984: 310: 1213-1217.
50. Christensen C, Jørgensøn L. Morphine-6-glucuronide has high affinity for the opioid receptor. Pharmacol Toxicol 1987: 60: 75-76.
51. Osborne R, Joel S, Trew D, Slevin M. Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther 1990: 47: 12-19.
52. McQuay HJ, Carroll D, Faura CC, Gavaghan DJ, Hand CW, Moore RA. Oral morphine in cancer pain: influences on morphine and metabolite concentration. Clin Pharmacol Ther 1990: 48: 236-44.
53. Boerner U, Abbott S, Roe R. The metabolism of morphine and heroin in man. Drug Metab Rev 1975: 4: 39-73.
54. Sawe J, Dahlstrom B, Paalzow L, Rane A. Morphine Kinetics in Cancer Patients. Clin Pharmacol Ther 1981: 30: 629-635.
55. Shimomura K, Kamata O, Ueki S, Ida S, Oguri K, Yoshimura H et al. Analgesic effect of morphine glucuronides. Tohoku J Exp Med 1971: 105: 45-52.
56. Sullivan AF, McQuay HJ, Bailey D, Dickenson AH. The spinal antinociceptive actions of morphine metabolites morphine-6-glucuronide and normorphine in the rat. Brain Res 1989: 482: 219-24.
57. Hand CW, Blunnie WP, Claffey LP, McShane AJ, McQuay HJ, Moore RA. Potential analgesic contribution from morphine-6-glucuronide in CSF [letter]. Lancet 1987: 2: 1207-1208.
58. McQuay HJ, Moore RA, Hand CW, Sear JW. Potency of oral morphine [letter]. Lancet 1987: 2: 1458-1459.
59. Osborne R, Joel S, Trew D, Slevin M. Analgesic activity of morphine-6-glucuronide. Lancet 1988: 1: 828.
60. Twycross R, Wald S. Longterm use of diamorphine in advanced cancer. In: Bonica J, Albe-Fessard D, eds. Advances in Pain Research and Therapy, Vol. 1. New York: Raven Press, 1976: 653-661.
61. McQuay H, Moore A. Be aware of renal function when prescribing morphine [letter]. Lancet 1984: 2: 284-285.
62. Osborne R, Joel S, Slevin M. Morphine intoxication in renal failure: the role of morphine-6-glucuronide. Br Med J 1986: 292: 1548-1549.
63. Patwardhan R, Johnson R, Hoyumpa A, Sheehan J, Desmond P, Wilkinson G et al. Normal metabolism of morphine in cirrhosis. Gastroenterology 1981: 81: 1006-1011.
64. Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson J, Sawe J. The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol 1990: 29: 289-297.
65. Laidlaw J, Read A, Sherlock S. Morphine tolerance in hepatic cirrhosis. Gastroenterology 1961: 40: 389-396.
66. Moulin D. Morphine in chronic pain. Lancet, in press.
67. Agenas I, Gustafsson L, Rane A, Sawe J. Analgetika-terapi for cancerpatienter. Läkartidningen 1982: 79: 287-289.
68. Stratton Hill C, Fields W. Drug treatment of cancer pain in a drug oriented society. Advances in Pain Research and Therapy, Vol. 11. New York: Raven Press, 1989.
69. Brena S, Sanders S. Opioids in nonmalignant pain: questions in search of answers. Clin J Pain 1991: 7: 342-345.
70. Hardy P. Use of opiates in treating chronic benign pain. Br J Hosp Med 1991: 45: 257.
71. Glynn C, McQuay H, Jadad A, Carroll D. Response to controversy corner: "Opioids in nonmalignant pain: questions in search of answers". Clin J Pain 1991: 7: 346.